![Are CAR-T therapies living up to their hype? A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants Are CAR-T therapies living up to their hype? A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants](https://ebm.bmj.com/content/ebmed/26/3/98/F2.large.jpg)
Are CAR-T therapies living up to their hype? A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants
![Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients | Cell Death & Disease Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients | Cell Death & Disease](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41419-020-2388-1/MediaObjects/41419_2020_2388_Fig1_HTML.png)
Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients | Cell Death & Disease
![CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies - The Lancet Haematology CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies - The Lancet Haematology](https://www.thelancet.com/cms/attachment/16e2634e-3679-4361-9fb7-ec7189202d1f/gr1_lrg.jpg)
CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies - The Lancet Haematology
![Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients | Cell Death & Disease Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients | Cell Death & Disease](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41419-020-2388-1/MediaObjects/41419_2020_2388_Fig4_HTML.png)
Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients | Cell Death & Disease
![Frontiers | Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials Frontiers | Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials](https://www.frontiersin.org/files/MyHome%20Article%20Library/544754/544754_Thumb_400.jpg)
Frontiers | Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials
Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy | PLOS Computational Biology
![Successful CD19 CAR T Cell Therapy Requires Prior Lymphodepletion Mice... | Download Scientific Diagram Successful CD19 CAR T Cell Therapy Requires Prior Lymphodepletion Mice... | Download Scientific Diagram](https://www.researchgate.net/publication/321909787/figure/fig5/AS:659965517783041@1534359449837/Successful-CD19-CAR-T-Cell-Therapy-Requires-Prior-Lymphodepletion-Mice-bearing.png)
Successful CD19 CAR T Cell Therapy Requires Prior Lymphodepletion Mice... | Download Scientific Diagram
![Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients | Cell Death & Disease Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients | Cell Death & Disease](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41419-020-2388-1/MediaObjects/41419_2020_2388_Fig3_HTML.png)